Inherited hypercoagulable states

Vascular Medicine

Volumn 2, Issue 4, 1997, Pages 313-320

  Rao, A Koneti ^a   Sheth, Sunita ^a   Kaplan, Robert ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antithrombin; Factor V Leiden; Hypercoagulable states; Hyperhomocysteinemia; Protein C; Thrombophilia

Indexed keywords

ACTIVATED PROTEIN C RESISTANCE; ANTITHROMBIN DEFICIENCY; BLOOD CLOTTING; CLINICAL FEATURE; DYSFIBRINOGENEMIA; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; REVIEW; RISK ASSESSMENT;

EID: 0031412374     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358863X9700200407     Document Type: Review

References (80)

1. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 116: 754-61.
2. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993; 90: 1004-1008.
3. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway detective in majority of thrombophilic patients. Blood 1993; 82: 1989-93.
4. Bertina RM, Koeleman BP, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
5. Voorberg J, Roelse J, Koopman R et al. Association of idiopathic venous thromboembolism with single point mutation at Arg506 of factor V. Lancet 1994; 343: 1535-36.
6. Poort SR, Rosendaal FR, Reitsma PH et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
7. Lane DA, Bayston T, Olds RJ et al. Antithrombin III mutation database: 2nd (1997) update. Thromb Haemost 1997; 77: 197-211.
8. Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb Haemost 1987; 58: 1094.
9. Dahlback B Resistance to activated protein C as risk factor for thrombosis, molecular mechanisms, laboratory investigation, and clinical management Semin Hematol 1997; 34(3): 217-34.
10. Reitsma PH, Bernardi F, Doig RG et al. Protein C deficiency: a database of mutations, 1995 update. Thromb Haemost 1995; 73: 876-89.
11. Aiach M, Borgei D, Baussem P, Emmerich J, Alhenc-Gelas M, Gandrille S. Protein C and protein S deficiency Semin Hematol 1997; 34: 205-17.
12. Ohlin AK, Marlar RA. The first mutation identified in the thrombomodulin gene in a 45 year old man presenting with thromboembolic disease Blood 1995; 85: 330-36
13. Prins MH, Hirsh J. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. Arch Intern Med 1991; 151: 1721-31.
14. Gram J, Sidelmann J, Jespersen J. Does low protein concentration of tissue-type plasminogen activator predict a low risk of spontaneous deep vein thrombosis? Thromb Haemost 1995; 74: 718-21.
15. Dolan G, Preston FE. Familial plasminogen deficiency and thromboembolism. Fibrinolysis 1988; 2(S2): 26-34.
16. Santori MT, Patrassi GM, Theodoridis P, Perin A, Peilrogrande F, Girolami A. Heterozygous type I plasminogen deficiency is associated with an increased risk for thrombosis: a statistical analysis in 20 kindreds. Blood Coagul Fibrinolysis 1994; 5: 889-93.
17. Martinez J. Quantitative and qualitative disorders of fibrinogen. In Hoffman R, Benz EJ JT, Shattil SJ, Furie B, Cohen HJ, Silverstein LE. Hematology. Basic principles and practice, second edition. New York: Churchill Livingstone, 1995; 1703-17.
18. Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Thromb Haemost 1995; 73: 151-61.
19. DiAngelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997; 90: 1-11.
20. DeStefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes and management Blood 1996; 87: 3531-44.
21. Motulsky A. Nutritional ecogenetics: Homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid. Am J Hum Genet 1996; 58: 17-20.
22. Kang SS, Zhou J, Wong PWK, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: A thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43: 414-21
23. Naurath JH, Joosten E, Riezler R, Stabler SP, Allen RH, Lindenbaum J. Effects of vitamin B12, folate and vitamin B6 supplement in elderly people with normal serum vitamin concentration Lancet 1995; 346: 85-89.
24. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994; 14: 1080-83
25. Den Heijer M, Blom HJ, Gerrits WBJ et al. Is hyperhomocysteinaemia a risk factor for venous thrombosis? Lancet 1995; 345: 882-85.
26. Den Heijer M, Koster T, Blom HJ et al Hyperhomocysteinemia as a risk factor for deep vein thrombosis. N Engl J Med 1996; 33:4: 759-62.
27. Mandel H, Brenner B, Berant M et al. Coexistence of hereditary homocystinuria and factor V Leiden - effect on thrombosis. N Engl J Med 1996; 334: 763-68
28. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis J Clin Invest 1976; 58: 731-41.
29. Upchurch GR Jr, Welch GN, Freedman JE, Loscalzo J. Homocysteine attenuates endothelial glutathione peroxidase and thereby potentiates peroxide-mediated injury. Circulation 1995; 92: I-228.
30. Loscalzo J. The oxidant stress of homocyst(e)inemia. J Clin Invest 1996; 98: 5-7.
31. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95: 1119-21.
32. Engesser L, Kluft C, Briet E, Brommer EJ. Familial elevation of plasma histidine rich glycoprotein in a family with thrombophilia. Br J Haematol 1987; 67: 355-58.
33. Castaman G, Ruggeri M, Burei F, Rodeghiero F High levels of histidine rich glycoprotein deficiency and familial thrombophilia: a new case Thromb Res 1993; 69: 279-305.
34. Simioni P, Lazarro AR, Coser E, Salmistraro G, Girolami A. Hereditary heparin cofactor II deficiency and thrombosis: report of six patients belonging to two separate kindreds. Blood Coagul Fibrinolysis 1990; 1: 351-56.
35. Sié P, Dupouy D, Pichon J, Boneu B. Constitutional heparin cofactor II deficiency associated with recurrent thrombosis. Lancet 1985; ii: 414-16.
36. Mannhalter C, Fischer M, Hopmeier P, Deutsch E. Factor XII activity and antigen concentrations in patients suffering from recurrent thrombosis. Fibrinolysis 1987; 1: 259-63.
37. Halbmayer WM, Mannhalter C, Feichtinger C, Rubi K, Fischer M. The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and/or arterial thromboembolism. Thromb Haemost 1992; 68: 285-90.
38. Levi M, Hack CE, de Boer JP, Brandjes DPM, Buller HR, Cate JWT. Reduction of contact activation related fibrinolytic activity in factor XII deficient patients J Clin Invest 1991; 88: 1155-60.
39. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-17.
40. DeStefano V, Leone G, Mastangelo S et al. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C and protein S. Thromb Haemost 1994; 72: 352-58.
41. Demers C, Ginsberg JS, Hirsh J, Henderson P, Blajchman MA. Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. Ann Intern Med 1992; 116: 754-61.
42. Pabinger I, Schneider B, and the GTH Group on Natural Inhibitors. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. Thromb Haemost 1994; 71: 548-52.
43. Vandenbroucke JP, Koster T, Briet E et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-57.
44. van Boven HH, Vandenbroucke JP, Westendorp RGJ, Rosendaal FR. Mortality and causes of death in inherited antithrombin deficiency. Thromb Haemost 1997; 77: 452-55
45. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-508.
46. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
47. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich HP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction. N Engl J Med 1995; 332: 912-17.
48. Tait RC, Walker ID, Reeitsma PH et al. Prevalence of protein C deficiency in the healthy population Thromb Haemost 1995; 73: 87-93.
49. Miletich J, Sherman L, Broze G Jr. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317: 991-96.
50. Tait RC, Walker ID, Islam SIA et al Influence of demographic factors on antithrombin III activity in a healthy population. Br J Haematol 1993; 84: 476-80.
51. Briet E, Engesser L, Brommer EJP, Broekmans W, Bertina RM. Thrombophilia: its causes and a rough estimate of its prevalence. Thromb Haemost 1987; 58: 39.
52. Ben Tal O, Zivelin A, Seligsohn U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. Thromb Haemost 1989; 61: 50-54.
53. Tabernero MD, Tomas JF, Alberca I, Orfao A, Lopez Borrasca A, Vicente V. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol 1991; 36: 249-54.
54. Heijboer H, Brandjes DP, Buller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in out-patients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512-16.
55. Koster T, Rosendaal FR, Briet E et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 1995; 85: 2756-61
56. Rosendaal FR. Risk factors for venous thrombosis: prevalence, risk and interaction. Semin Hematol 1997; 34: 171-87.
57. Miletich JP, Prescott SM, White R et al. Inherited predisposition to thrombosis. Cell 1993; 72: 749-58.
58. Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-35
59. Zoller B, Berntsdotter A, Garcia de Frutos P, Dahlback B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-23.
60. van Boven HH, Reitsma PH, Rosendaal FR et al. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996; 75: 417-21
61. Ireland H, Bayston TA, Chowdhury V et al. Factor V Leiden as an independent risk factor for thrombosis and antithrombin deficiency type II: heparin binding site Thromb Haemost 1995; 73: 1361 (abstract).
62. Hirsh J, Prins MH, Samama M. Therapeutic agents and their practical use in thrombotic disorders. Approach to the thrombophilic patient for hemostasis and thrombosis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW eds. Hemostasis and thrombosis: basic principles and clinical practice, second edition. Philadelphia: JB Lippincott, 1994: 1543-61.
63. 506→ Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336: 399-403.
64. Ridker PM, Miletich JP, Stampfer MJ et al. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism Circulation 1995; 92: 2800-802
65. Prandoni P, Lensing AWA, Cogo A et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
66. Levine MN, Hirsh J, Gent M et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74: 606-11.
67. Schulman S, Granqvist S, Holmstrom M et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336: 393-98.
68. Marciniak E, Gockerman JP. Heparin induced decrease in circulating antithrombin III. Lancet 1973; ii: 581-84.
69. Rao AK, Niewiarowski S, Guzzo J, Day HJ. Antithrombin-III levels during heparin therapy. Thromb Res 1981; 24: 181-86.
70. Jorquera JI, Montoro JM, Fernandez M, Aznar JA, Aznar J. Modified test for activated protein C resistance. Lancet 1994; 344: 1162-63.
71. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
72. Goldstein F, Stampfer MJ, Goldhaber SZ et al Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-87.
73. Jick H, Derby LE, Myers MW, Vasilaskis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981-83.
74. Vandenbroucke JP, Helmerhorst FM. Risk of venous thrombosis with hormone-replacement therapy. Lancet 1996; 348: 972.
75. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80.
76. Preston FE, Rosendaal FR, Walker ID et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348: 913-16.
77. Conard J, Horellou MH, Van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in ATIII, protein C or protein S: study of 78 women. Thromb Haemost 1990; 63: 319-320.
78. DeStefano V, Leone G, Mastrangelo S et al. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Hemost 1994; 71: 799-800.
79. Koeleman BPC, Reitsma PH, Bertina RM. Familial thrombophilia: a complex genetic disorder Semin Hematol 1997; 34: 256-64.
80. Seligsohn W, Zirelin A. Thrombophilia as a multigene disorder. Thromb Haemost 1997; 78: 297-301.